- Home
- INSP vs PTGX Comparison
INSP vs PTGX Comparison
Compare INSP & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSP
- PTGX
- Stock Information
- Founded
- INSP 2007
- PTGX 2006
- Country
- INSP United States
- PTGX United States
- Employees
- INSP N/A
- PTGX N/A
- Industry
- INSP Medical/Dental Instruments
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- INSP Health Care
- PTGX Health Care
- Exchange
- INSP Nasdaq
- PTGX Nasdaq
- Market Cap
- INSP 3.8B
- PTGX 4.0B
- IPO Year
- INSP 2018
- PTGX 2016
- Fundamental
- Price
- INSP $77.31
- PTGX $79.23
- Analyst Decision
- INSP Buy
- PTGX Strong Buy
- Analyst Count
- INSP 15
- PTGX 8
- Target Price
- INSP $154.00
- PTGX $71.13
- AVG Volume (30 Days)
- INSP 1.1M
- PTGX 1.6M
- Earning Date
- INSP 11-03-2025
- PTGX 11-06-2025
- Dividend Yield
- INSP N/A
- PTGX N/A
- EPS Growth
- INSP 756.73
- PTGX N/A
- EPS
- INSP 1.74
- PTGX 0.80
- Revenue
- INSP $861,312,000.00
- PTGX $209,180,000.00
- Revenue This Year
- INSP $14.85
- PTGX N/A
- Revenue Next Year
- INSP $14.64
- PTGX $243.08
- P/E Ratio
- INSP $44.59
- PTGX $98.41
- Revenue Growth
- INSP 22.05
- PTGX N/A
- 52 Week Low
- INSP $70.77
- PTGX $33.31
- 52 Week High
- INSP $216.01
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- INSP 44.12
- PTGX 67.60
- Support Level
- INSP $75.89
- PTGX $62.24
- Resistance Level
- INSP $82.40
- PTGX $93.25
- Average True Range (ATR)
- INSP 3.01
- PTGX 4.93
- MACD
- INSP 0.97
- PTGX 1.47
- Stochastic Oscillator
- INSP 56.19
- PTGX 54.77
About INSP Inspire Medical Systems Inc.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.